Investing.com - Jefferies initiated coverage on Vor Biopharma, Inc. (NASDAQ:VOR) with a buy rating and a price target of $50.00. With the stock currently trading at $14.48 and a market cap of $601 million, analysts see substantial upside potential, with price targets ranging from $30 to $55.
The company pivoted to autoimmune diseases in June 2025, licensing telitacicept globally excluding Greater China from RemeGen. The drug is approved in China for systemic lupus erythematosus, rheumatoid arthritis, and generalized myasthenia gravis, with filings for Sjögren's syndrome and IgA nephropathy.
Jefferies expects pivotal data for generalized myasthenia gravis in the first half of 2027, with a pivotal trial for Sjögren's syndrome currently underway. The firm estimates the combined commercial opportunity exceeds $2 billion.
Vor Biopharma holds $450 million in cash through mid-2028 and the generalized myasthenia gravis launch. According to InvestingPro data, the company holds more cash than debt on its balance sheet, with a strong current ratio of 9.16, indicating solid financial flexibility to fund its clinical programs. Investors should note the stock's high volatility, with a beta of 2.04 and a 20% gain over the past week. In a China-run pivotal trial, telitacicept delivered placebo-adjusted MG-ADL gains above approved and late-stage comparators.
The dual BAFF/APRIL inhibition mechanism modulates the immune system without broad B-cell depletion and addresses all pathogenic antibody classes including IgG, IgA, and IgM. For deeper insights, InvestingPro offers a comprehensive Pro Research Report on VOR, one of 1,400+ US equities covered with expert analysis and actionable intelligence.
In other recent news, Vor Bio has announced a significant financial development. The company entered into a securities purchase agreement to raise approximately $75 million through a private placement. This transaction involves the sale of 5,338,078 shares of common stock at a price of $14.05 per share. The private placement is led by TCGX, a new investor, and is anticipated to close around March 30, 2026, pending customary closing conditions. Vor Bio did not utilize a placement agent for this transaction. This influx of capital is expected to support the company's ongoing operations and strategic initiatives. These recent developments underscore Vor Bio's efforts to bolster its financial position.